Serine–arginine protein kinase 1 (SRPK1) inhibition as a potential novel targeted therapeutic strategy in prostate cancer

Cancer prevalence estimates in Europe at the beginning of 2000

(2013) G. Gatta et al.   ANNALS OF ONCOLOGY

European cancer mortality predictions for the year 2013

(2013) M. Malvezzi et al.   ANNALS OF ONCOLOGY

Cancer statistics, 2013

(2013) Rebecca Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Angiogenesis and anti-angiogenic therapy in prostate cancer

(2013) Deborah Mukherji et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Novel Therapies for the Treatment of Advanced Prostate Cancer

(2013) J. M. Clarke et al.   CURRENT TREATMENT OPTIONS IN ONCOLOGY

Markers of Response for the Antiangiogenic Agent Bevacizumab

(2013) Diether Lambrechts et al.   JOURNAL OF CLINICAL ONCOLOGY

SRPK1 contributes to malignancy of hepatocellular carcinoma through a possible mechanism involving PI3K/Akt

(2013) Bo Zhou et al.   MOLECULAR AND CELLULAR BIOCHEMISTRY

Metastatic castration-resistant prostate cancer: new therapies, novel combination strategies and implications for immunotherapy

(2013) C G Drake et al.   ONCOGENE

Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches

(2013) T Karantanos et al.   ONCOGENE

Detection of VEGF-Axxxb Isoforms in Human Tissues

(2013) David O. Bates et al.   PLoS One

Incidence and mortality trends for four major cancers in the elderly and middle-aged adults: An international comparison

(2013) Alberto Quaglia et al.   SURGICAL ONCOLOGY-OXFORD

SRPK1 inhibitionin vivo: modulation of VEGF splicing and potential treatment for multiple diseases: Figure 1

(2012) Sebastian Oltean et al.   BIOCHEMICAL SOCIETY TRANSACTIONS

Association between VEGF Splice Isoforms and Progression-Free Survival in Metastatic Colorectal Cancer Patients Treated with Bevacizumab

(2012) D. O. Bates et al.   CLINICAL CANCER RESEARCH

Randomized, Double-Blind, Placebo-Controlled Phase III Trial Comparing Docetaxel and Prednisone With or Without Bevacizumab in Men With Metastatic Castration-Resistant Prostate Cancer: CALGB 90401

(2012) William Kevin Kelly et al.   JOURNAL OF CLINICAL ONCOLOGY

The Akt-SRPK-SR Axis Constitutes a Major Pathway in Transducing EGF Signaling to Regulate Alternative Splicing in the Nucleus

(2012) Zhihong Zhou et al.   MOLECULAR CELL

Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy

(2012) Howard I. Scher et al.   NEW ENGLAND JOURNAL OF MEDICINE

Elevated Expression of the Serine-Arginine Protein Kinase 1 Gene in Ovarian Cancer and Its Role in Cisplatin Cytotoxicity In Vitro

(2012) Kunle Odunsi et al.   PLoS One

Abnormal Expression of the Pre-mRNA Splicing Regulators SRSF1, SRSF2, SRPK1 and SRPK2 in Non Small Cell Lung Carcinoma

(2012) Stephanie Gout et al.   PLoS One

WT1 Mutants Reveal SRPK1 to Be a Downstream Angiogenesis Target by Altering VEGF Splicing

(2011) Elianna M. Amin et al.   CANCER CELL

Hallmarks of Cancer: The Next Generation

(2011) Douglas Hanahan et al.   CELL

A phase II study of lapatinib, a dual EGFR and HER-2 tyrosine kinase inhibitor, in patients with castration-resistant prostate cancer

(2011) Young E. Whang et al.   UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS

Regulation of Vascular Endothelial Growth Factor (VEGF) Splicing from Pro-angiogenic to Anti-angiogenic Isoforms

(2009) Dawid G. Nowak et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

VEGF165b, an antiangiogenic VEGF-A isoform, binds and inhibits bevacizumab treatment in experimental colorectal carcinoma: balance of pro- and antiangiogenic VEGF-A isoforms has implications for therapy

(2008) A H R Varey et al.   BRITISH JOURNAL OF CANCER

The endogenous anti-angiogenic VEGF isoform, VEGF165b inhibits human tumour growth in mice

(2008) E S Rennel et al.   BRITISH JOURNAL OF CANCER